Cutler Group’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-34,900
Closed -$33K 5218
2021
Q4
$33K Buy
34,900
+4,800
+16% +$6.31K ﹤0.01% 2717
2021
Q3
$43K Sell
30,100
-27,700
-48% -$38.8K ﹤0.01% 2632
2021
Q2
$62K Sell
57,800
-5,200
-8% -$9.15K ﹤0.01% 2295
2021
Q1
$56K Buy
63,000
+39,100
+164% +$89.5K ﹤0.01% 2262
2020
Q4
$10K Buy
23,900
+22,100
+1,228% +$46.5K ﹤0.01% 3168
2020
Q3
$1K Buy
+1,800
New +$4.94K ﹤0.01% 4219

Other funds holding ADMA

Cutler Group's ADMA Position: Q1 2023 in Review

Cutler Group sold out of ADMA Biologics (ADMA) in Q1 2023, closing a stake of 2,000 shares — an estimated $7K sold.

Cutler Group first reported a position in ADMA in Q1 2019 and held it in 10 quarters. The position peaked at $87K in Q1 2021. 163 funds tracked by Wall St. Rank hold ADMA as of Q1 2023.

  • Cutler Group reported no remaining ADMA Biologics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 2,000 ADMA Biologics shares in Q1 2023, an estimated $7K.
  • Cutler Group first reported a position in ADMA Biologics in Q1 2019 and held it in 10 quarters.
  • Cutler Group's ADMA Biologics position peaked at $87K in Q1 2021.
  • 163 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.